It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Staphylococcus aureus is a predominant cause of chronic lung infections. While the airway environment is rich in highly sialylated mucins, the interaction of S. aureus with sialic acid is poorly characterized. Using S. aureus USA300 as well as clinical isolates, we demonstrate that quorum-sensing dysfunction, a hallmark of S. aureus adaptation, correlates with a greater ability to consume free sialic acid, providing a growth advantage in an air-liquid interface model and in vivo. Furthermore, RNA-seq experiment reveals that free sialic acid triggers transcriptional reprogramming promoting S. aureus chronic lifestyle. To support the clinical relevance of our results, we show the co-occurrence of S. aureus, sialidase-producing microbiota and free sialic acid in the airway of patients with cystic fibrosis. Our findings suggest a dual role for sialic acid in S. aureus airway infection, triggering virulence reprogramming and driving S. aureus adaptive strategies through the selection of quorum-sensing dysfunctional strains.
This study by Ding et al reveals that the quorum-sensing dysfunction typically encountered in lung-adapted Staphylococcus aureus isolates could be selected by an enhanced ability to consume sialic acid released from airway mucins by the microbiota.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Université Paris Cité, INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker Enfants Malades, Paris, France (GRID:grid.465541.7) (ISNI:0000 0004 7870 0410)
2 Université Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, Lille, France (GRID:grid.503422.2) (ISNI:0000 0001 2242 6780)
3 INSERM U1016, CNRS UMR8104, Université Paris Cité, Team «Mucosal Microbiota in Chronic Inflammatory Diseases», Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602)
4 Genoscope, UMR8030, Laboratory of Systems & Synthetic Biology (LISSB), Xenome team, Evry, France (GRID:grid.434728.e) (ISNI:0000 0004 0641 2997)
5 Physiopathology and epidemiology of equine diseases (PhEED), RD 675, Anses, Laboratory of Animal Health in Normandy, Goustranville, France (GRID:grid.15540.35) (ISNI:0000 0001 0584 7022)
6 Université Paris Cité, Institut de physique du globe de Paris, CNRS, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602)
7 AP-HP Centre Université de Paris Cité, Department of Clinical Microbiology, Necker-Enfants Malades Hospital, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602)
8 Université Paris Cité, INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker Enfants Malades, Paris, France (GRID:grid.465541.7) (ISNI:0000 0004 7870 0410); AP-HP Centre Université de Paris Cité, Department of Clinical Microbiology, Necker-Enfants Malades Hospital, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602)